These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season. Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156 [TBL] [Abstract][Full Text] [Related]
3. Respiratory tract infections caused by respiratory syncytial virus in children. Diagnosis and treatment. Van Woensel JB; Kimpen JL; Brand PL Minerva Pediatr; 2001 Apr; 53(2):99-106. PubMed ID: 11404731 [TBL] [Abstract][Full Text] [Related]
4. Prevention of respiratory syncytial virus infection in high risk infants. Prince AM; Jacobs RF J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047 [TBL] [Abstract][Full Text] [Related]
5. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627 [TBL] [Abstract][Full Text] [Related]
6. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704 [TBL] [Abstract][Full Text] [Related]
7. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Broughton S; Roberts A; Fox G; Pollina E; Zuckerman M; Chaudhry S; Greenough A Thorax; 2005 Dec; 60(12):1039-44. PubMed ID: 16227330 [TBL] [Abstract][Full Text] [Related]
8. New drugs and treatment for respiratory syncytial virus. Maggon K; Barik S Rev Med Virol; 2004; 14(3):149-68. PubMed ID: 15124232 [TBL] [Abstract][Full Text] [Related]
9. Palivizumab. Gupta D; Gupta P Indian Pediatr; 2001 Nov; 38(11):1265-9. PubMed ID: 11721066 [No Abstract] [Full Text] [Related]
10. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Ottolini MG; Curtis SR; Mathews A; Ottolini SR; Prince GA Bone Marrow Transplant; 2002 Jan; 29(2):117-20. PubMed ID: 11850705 [TBL] [Abstract][Full Text] [Related]
14. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Cardenas S; Auais A; Piedimonte G Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163 [TBL] [Abstract][Full Text] [Related]
15. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776 [TBL] [Abstract][Full Text] [Related]
16. Synagis now registered for the prevention of RSV disease in children with CHD. Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001434 [No Abstract] [Full Text] [Related]